Nechama Keller-Sabel
Psychiatric/Mental Health · Suffern, NYNPI 1346608221
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,699 of the $14,570 with a category attached, or 80.3%. 23 manufacturers reported payments, led by AbbVie at 36.9% of the total. Reporting peaked in 2021 at $5,314 and has fallen 66.6% since, to $1,776 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Otsuka America Pharmaceutical, Inc.$2K
- Axsome Therapeutics, Inc.$2K
- Bausch Health US, LLC$1K
- Avanir Pharmaceuticals, Inc.$1K
- Alkermes, Inc.$854
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$2,75019%
- Food & beverage$11,69980%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $5,382 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,669 |
| Axsome Therapeutics, Inc. | 50 | $1,585 |
| Bausch Health US, LLC | 76 | $1,364 |
| Avanir Pharmaceuticals, Inc. | 47 | $1,093 |
| Alkermes, Inc. | 31 | $854 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $733 |
| Corium, LLC | 18 | $393 |
| Supernus Pharmaceuticals, Inc. | 17 | $345 |
| Neos Therapeutics, LP | 9 | $181 |
| Tris Pharma Inc | 8 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $148 |
| Arbor Pharmaceuticals, Inc. | 9 | $135 |
| Jazz Pharmaceuticals Inc. | 5 | $98 |
| Sunovion Pharmaceuticals Inc. | 5 | $86 |
| Azurity Pharmaceuticals, Inc. | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 3 | $58 |
| E.r. Squibb & Sons, L.L.C. | 2 | $58 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Johnson & Johnson | 2 | $41 |
| Lilly USA, LLC | 1 | $27 |
| Lundbeck LLC | 1 | $20 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,570 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 18 | $25,661 |
| TrintellixVortioxetine Hydrobromide | 15 | $6,927 |
| Vilazodone Hcl | 29 | $1,409 |
| Bupropion XlBupropion Hcl | 32 | $772 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $645 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $474 |
| Alprazolam | 47 | $246 |
| Bupropion Hcl SrBupropion Hcl | 19 | $211 |
| Quetiapine Fumarate | 14 | $208 |
| Clonazepam | 21 | $182 |
| Bupropion Hcl | 13 | $159 |
| Fluoxetine Hcl | 16 | $151 |
| Gabapentin | 25 | $143 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $96 |
| Escitalopram Oxalate | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,669 | $25,66118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $148 | $6,92715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Suffern
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.